Overview of everolimus manufacturers and applicable patient groups

Everolimus, developed by the Swiss pharmaceutical company Novartis, is an oral inhibitor of the mammalian target of rapamycin protein (mTOR). By blocking the mTOR signaling pathway, it effectively inhibits the growth and proliferation of tumor cells and has shown excellent results in the treatment of various diseases. The applicable patient groups of everolimus are described in detail below.

For postmenopausal female patients with advanced hormone receptor-positive, HER2-negative breast cancer, if letrozole or anastrozole treatment fails, the combination therapy of everolimus and exemestane can become a new treatment option and help prolong the progression-free survival of the patients.

For adult patients with unresectable, locally advanced or metastatic progressive neuroendocrine tumors of pancreatic origin, everolimus also shows significant therapeutic effects, can effectively control tumor growth, and prolong survival for patients.

For adult patients with unresectable, locally advanced or metastatic advanced well-differentiated non-functional gastrointestinal or pulmonary disease, everolimus provides a non-surgical treatment option to help patients meet the challenge of cancer.

In the field of renal cancer treatment, everolimus is suitable for adult patients with advanced renal cell carcinoma who have failed treatment with sunitinib or sorafenib, bringing them new treatment hope.

In addition, in adult patients with renal angiomyolipomas associated with tuberous sclerosis complex (TSC), everolimus can help control tumor growth and reduce the need for surgical intervention.

For adult and pediatric patients aged 1 year and older with TSC-related subependymal giant cell astrocytoma who require treatment but cannot be radically resected, everolimus also shows good therapeutic effects, helping to control the tumor and reduce surgical risks.

Finally, everolimus is also suitable for adjuvant treatmentIn adult and pediatric patients aged 2 years and above with TSC-related partial-onset epilepsy, it can help control epileptic seizures and improve the patient's quality of life.

In summary, everolimus has become an important treatment option for patients with a variety of cancers and tuberous sclerosis-related diseases due to its broad scope of application and significant therapeutic effects. However, before use, patients must consult a professional physician to ensure the safety and effectiveness of the treatment plan.